Viridian Therapeutics (VRDN) Announces Proposed $150M Share and Warrant Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Viridian Therapeutic (VRDN) PT Raised to $31 at Goldman Sachs
September 12, 2024 5:07 AM EDTGoldman Sachs analyst Richard Law raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $31.00 (from $25.00) while maintaining a Buy rating.
The analyst comments "We update our model to reflect increased POS for veligrotug (VRDN-001) following positive topline results from the Ph. 3 THRIVE... More
